-
Cardiogenesis (Irvine, Califonrnia), a developer of surgical products for transmyocardial revascularization (TMR) reported FDA approval of its PEARL (Port Enabled Angina Relief using Laser) 5.0 Robotic Delivery System.
-
CVRx (Minneapolis) last month received the CE mark for its Rheos Baroreflex Hypertension Therapy System, which it said is the only implantable device designed to control hypertension.
-
Donald Wood has been named VP of operations for Abaxis (Union City, California), a manufacturer of portable blood analysis systems. Wood most recently served as VP of operations at Cholestech.
-
In today's microwave society, where results are sometimes wanted yesterday, coronary stent procedures have proven to be an amicable solution for treating diseased arteries.
-
Alpha Innotech, a provider of bioanalytical systems for drug discovery and life science research, reported a product development and OEM supply agreement with R&C Biogenius (Los Angeles).
-
ImaRx Therapeutics and Royal Philips Electronics reported a new research alliance focused on using Philips' ultrasound technology as part of ImaRx's SonoLysis program to develop a new treatment for acute ischemic stroke.
-
In another move designed to deal with big debt and stagnating device sales, Boston Scientific (Natick, Massachusetts) reported its long-anticipated restructuring.
-
Direct Flow Medical (Santa Rosa, California), a company developing a minimally invasive implant to treat patients with heart valve disease, reported completing its Series B financing and initiating clinical trials in Europe.
-
On one level at least, Europe is only an idea. It has a flag and an anthem, but no constitution nor a mandate to regulate health policies and practices.
-
Over the past five years significant advances have marched out of the laboratories and clinical trial factories of the cardiovascular disease sector.
